MXPA06007829A - Composicion farmaceutica directamente comprimible para la administracion oral de 42-ester de rapamicina con acido 3-hidroxi-2-(hidroximetil)-2-metilpropionico. - Google Patents

Composicion farmaceutica directamente comprimible para la administracion oral de 42-ester de rapamicina con acido 3-hidroxi-2-(hidroximetil)-2-metilpropionico.

Info

Publication number
MXPA06007829A
MXPA06007829A MXPA06007829A MXPA06007829A MXPA06007829A MX PA06007829 A MXPA06007829 A MX PA06007829A MX PA06007829 A MXPA06007829 A MX PA06007829A MX PA06007829 A MXPA06007829 A MX PA06007829A MX PA06007829 A MXPA06007829 A MX PA06007829A
Authority
MX
Mexico
Prior art keywords
cci
admimistration
oral
pharmaceutical composition
directly compressible
Prior art date
Application number
MXPA06007829A
Other languages
English (en)
Inventor
Muhammad Ashraf
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MXPA06007829A publication Critical patent/MXPA06007829A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Abstract

Se describe CCI-779 micronizado; el 42-ester de rapamicina con acido 3-hidroxi-2-(hidroxi-ilmetil)-2-metilpropionico provee un metodo conveniente y efectivo para suministrar niveles terapeuticos de CCI-779 a un paciente.
MXPA06007829A 2004-01-08 2004-12-14 Composicion farmaceutica directamente comprimible para la administracion oral de 42-ester de rapamicina con acido 3-hidroxi-2-(hidroximetil)-2-metilpropionico. MXPA06007829A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53495104P 2004-01-08 2004-01-08
PCT/US2004/042178 WO2005070393A2 (en) 2004-01-08 2004-12-14 Directly compressible pharmaceutical composition of the rapamycin ester cci-779

Publications (1)

Publication Number Publication Date
MXPA06007829A true MXPA06007829A (es) 2006-09-01

Family

ID=34806893

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06007829A MXPA06007829A (es) 2004-01-08 2004-12-14 Composicion farmaceutica directamente comprimible para la administracion oral de 42-ester de rapamicina con acido 3-hidroxi-2-(hidroximetil)-2-metilpropionico.

Country Status (31)

Country Link
US (1) US20050152983A1 (es)
EP (1) EP1701698B1 (es)
JP (1) JP2007517879A (es)
KR (1) KR20060130162A (es)
CN (1) CN1921861A (es)
AR (1) AR047180A1 (es)
AT (1) ATE383859T1 (es)
AU (1) AU2004314213A1 (es)
BR (1) BRPI0418373A (es)
CA (1) CA2552595A1 (es)
CR (1) CR8491A (es)
CY (1) CY1107373T1 (es)
DE (1) DE602004011398T2 (es)
DK (1) DK1701698T3 (es)
EC (1) ECSP066757A (es)
ES (1) ES2298861T3 (es)
GT (1) GT200500003A (es)
HK (1) HK1090308A1 (es)
HN (1) HN2005000005A (es)
IL (1) IL176519A0 (es)
MX (1) MXPA06007829A (es)
NO (1) NO20062930L (es)
PA (1) PA8621201A1 (es)
PE (1) PE20050683A1 (es)
PL (1) PL1701698T3 (es)
PT (1) PT1701698E (es)
RU (1) RU2006122517A (es)
TW (1) TW200526213A (es)
UA (1) UA84903C2 (es)
WO (1) WO2005070393A2 (es)
ZA (1) ZA200605631B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004270154A1 (en) 2003-09-03 2005-03-17 Wyeth Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions containing the same
BRPI0509852A (pt) * 2004-04-14 2007-10-23 Wyeth Corp método para a preparação regioespecìfica dos derivados de 42-éster de rapamicina, preparação regioespecìfica do 42-éster de rapamicina, composição, produto, e, kit farmacêutico
AU2005238493A1 (en) * 2004-04-27 2005-11-10 Wyeth Labeling of rapamycin using rapamycin-specific methylases
MX2007009812A (es) * 2005-02-15 2007-10-23 Wyeth Corp Formulaciones en tableta de 42-ester de rapamicina con acido 3-hidroxi-2-(hidroximetil)-2-metilpropionico oralmente biodisponibles.
CN102579467A (zh) 2005-11-14 2012-07-18 阿里亚德医药股份有限公司 雷帕霉素衍生物在治疗癌症中的用途
WO2008003050A2 (en) * 2006-06-28 2008-01-03 Emisphere Technologies, Inc. Gallium nitrate formulations
US20080175887A1 (en) 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8430055B2 (en) 2008-08-29 2013-04-30 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
AU2011260016B2 (en) 2010-06-02 2013-08-22 Fresenius Kabi Oncology Ltd. Stable pharmaceutical compositions of Rapamycin esters
CA3007787C (en) 2010-06-03 2020-03-10 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk)
MY187999A (en) 2012-06-04 2021-11-08 Pharmacyclics Llc Crystalline forms of a bruton's tyrosine kinase inhibitor
WO2014018567A1 (en) 2012-07-24 2014-01-30 Pharmacyclics, Inc. Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
CN104721158B (zh) * 2013-12-24 2018-01-30 正大天晴药业集团股份有限公司 一种稳定的依维莫司片剂
TW202315634A (zh) 2015-03-03 2023-04-16 美商製藥公司 布魯東氏（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶抑制劑之醫藥調配物
US20190022073A1 (en) * 2015-09-03 2019-01-24 Nippon Kayaku Kabushiki Kaisha Pharmaceutical composition comprising rapamycin or derivative thereof
WO2017129772A1 (en) 2016-01-29 2017-08-03 Xellia Phamaceuticals Aps Stable pharmaceutical compositions of temsirolimus

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
JP2642486B2 (ja) * 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
US5536729A (en) * 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
US5928668A (en) * 1993-12-21 1999-07-27 Applied Analytical Industries, Inc. Method for dry blend compression of medicaments
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
RO120603B1 (ro) * 1996-08-22 2006-05-30 Research Triangle Pharmaceuticals Ltd. Compoziţie conţinând microparticule de substanţe insolubile în apă şi procedeu de preparare
US5989591A (en) * 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
US5985325A (en) * 1997-06-13 1999-11-16 American Home Products Corporation Rapamycin formulations for oral administration
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
US20040077677A1 (en) * 2002-09-17 2004-04-22 Wyeth Oral formulations
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
CN1829514A (zh) * 2003-07-25 2006-09-06 惠氏公司 Cci－779冻干制剂
KR20060057605A (ko) * 2003-08-07 2006-05-26 와이어쓰 Ｃｃｉ-779의 위치선택적 합성 방법
AU2004270154A1 (en) * 2003-09-03 2005-03-17 Wyeth Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions containing the same
US20060142422A1 (en) * 2004-12-07 2006-06-29 Toshikazu Kobayashi Hydrolysis resistant polyester compositions and articles made therefrom
MX2007009812A (es) * 2005-02-15 2007-10-23 Wyeth Corp Formulaciones en tableta de 42-ester de rapamicina con acido 3-hidroxi-2-(hidroximetil)-2-metilpropionico oralmente biodisponibles.

Also Published As

Publication number Publication date
ES2298861T3 (es) 2008-05-16
PA8621201A1 (es) 2005-12-23
WO2005070393A3 (en) 2006-09-28
CN1921861A (zh) 2007-02-28
CY1107373T1 (el) 2012-12-19
ECSP066757A (es) 2006-11-16
KR20060130162A (ko) 2006-12-18
US20050152983A1 (en) 2005-07-14
DK1701698T3 (da) 2008-05-05
GT200500003A (es) 2005-08-18
DE602004011398T2 (de) 2009-01-15
CA2552595A1 (en) 2005-08-04
WO2005070393A2 (en) 2005-08-04
PT1701698E (pt) 2008-03-27
AU2004314213A1 (en) 2005-08-04
DE602004011398D1 (de) 2008-03-06
PE20050683A1 (es) 2005-11-04
PL1701698T3 (pl) 2008-03-31
HK1090308A1 (en) 2006-12-22
IL176519A0 (en) 2006-10-05
TW200526213A (en) 2005-08-16
ZA200605631B (en) 2010-01-27
ATE383859T1 (de) 2008-02-15
CR8491A (es) 2008-08-21
JP2007517879A (ja) 2007-07-05
HN2005000005A (es) 2009-04-17
NO20062930L (no) 2006-10-02
BRPI0418373A (pt) 2007-05-22
UA84903C2 (ru) 2008-12-10
EP1701698A2 (en) 2006-09-20
RU2006122517A (ru) 2008-02-20
EP1701698B1 (en) 2008-01-16
AR047180A1 (es) 2006-01-11

Similar Documents

Publication Publication Date Title
MXPA06007829A (es) Composicion farmaceutica directamente comprimible para la administracion oral de 42-ester de rapamicina con acido 3-hidroxi-2-(hidroximetil)-2-metilpropionico.
IL166824A0 (en) Oral formulations
NO20061048L (no) Amorf rapamycin 42-ester med 3-hydroksy-2-(hydroksymetyl)-2-metylpropionsyre og dens farmasoytiske blandinger inneholdende samme
DE602006010776D1 (de) Piperazinylalkylpyrazol-Derivate zur Verwendung als selektive Calciumkanalblocker des T-Typs und Verfahren zu ihrer Herstellung
BR0311931A (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar uma doença ou condição mediada com hppar em um paciente
BRPI0518079A (pt) usos de um inibidor de mtor, de uma rapamicina, e de 42-éster de rapamicina com ácido 3-hidróxi-2- (hidroximetil) -2-metilpropiÈnico, composição farmacêutica, e, embalagem farmacêutica
SI1730147T1 (sl) Substituirane triazaspiro dekan onskespojine za zdravljenje obezitete
EP2392322A3 (en) Dosing regimes for trans-clomiphene
PL1730144T3 (pl) Podstawione pochodne 1,4,8-triazaspiro[4.5]dekan-2-onu
EA200501819A1 (ru) Способы и фармацевтические композиции для достоверного достижения приемлемых уровней тестостерона в сыворотке
EP1877004A4 (en) COMPOSITIONS AND METHODS FOR THE ADMINISTRATION OF RAPAMYCIN ANALOGUES WITH MEDICAL DEVICES FOR LONG-TERM EFFECT
DE60107399D1 (de) Pharmazeutische zusammensetzung mit gesteuerter freigabe enthaltend midodrin und/oder desglymidodrin
AU2003281257A8 (en) A novel use of rapamycin and structural analogues thereof
SV2006001989A (es) Composicion farmaceutica apta para la compresion directa para la administracion oral de cci - 779 ref. am-101453salvo
SI1701698T1 (sl) Neposredno stisljiv farmacevtski sestavek za peroralno dajanje CCI-779

Legal Events

Date Code Title Description
FG Grant or registration